Fingerprint
Dive into the research topics of 'Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
Philip E. Lammers, Magdolna Dank, Riccardo Masetti, Richat Abbas, Fiona Hilton, Jennifer Coppola, Ira Jacobs
Research output: Contribution to journal › Article
26
Citations
(Scopus)